Symbiotec Pharmalab Ltd.

NSE: SYMBIOTEC | BSE: 544889

Symbiotec Pharmalab Live Share Price Today, Share Analysis and Chart

Name: Symbiotec Pharmalab Ltd.: Is Infosys Ltd. worth buying?
Item: Symbiotec Pharmalab Ltd.
Rating: 0.275
Author: Trendlyne DVM scores

aboutSymbiotec Pharmalab was incorporated on September 20, 2002. The company is an R&D-driven;, science-based pharmaceutical and biotechnology player with capabilities in organic chemistry, biotechnology, and complex injectables, and a global leadership p... Read More

ANDA Approvals

-3.90(-0.31%)

298.3K

NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting

The next board meeting for Symbiotec Pharmalab is on 05 Nov 2026 for the purpose of Quarterly Results See details

- / 100

- / 100

No estimates available

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

4Positive8Negative

33.3%Pass in checklist

045

100

Check P/E Buy Sell Zone

Not enough data available

Symbiotec Pharmalab Stock Price Analysis

Day Price Range -0.3% 1 Day return	1246.3 (LTP) 1,2171,267.5 LowHigh
Week Price Range 7.0% 1 Week return	1246.3 (LTP) 1,1601,294.4 LowHigh
Month Price Range 5.9% 1 Month return	1246.3 (LTP) 1,067.61,309.9 LowHigh
52 Week Price Range 26.1% 1 Year return	1246.3 (LTP) 934.21,309.9 LowHigh

View full Price History/Seasonality

Competitors/Peers

Quarterly

Annual

Balance Sheet

Ratios

Cash Flow

Documents

Symbiotec Pharmalab quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Symbiotec Pharmalab Jun-2026 Quarterly Revenue is Rs 230 Cr which is growth of 6.8% YoY.
POSITIVE
Quarterly Net Profit Symbiotec Pharmalab Jun-2026 Quarterly Net Profit is Rs 47 Cr which is growth of 5.6% YoY.

Symbiotec Pharmalab Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
Indicator	Jun '26	Mar '26	Jun '25
TOTAL_SR_Q Total Rev. ⌄	230.4	231.8	215.7
SR_Q Operating Rev.	210.8	213.1	204.3
OI_Q Other Income	19.6	18.7	11.5
OEXPNS_Q Operating Exp.	151.6	164.1	141.9
OEXPNS_Q Operating Exp.	151.6	164.1	141.9
OP_Q Operating Profit	59.2	48.9	62.4
OPMPCT_Q Operating Profit Margin %	28.10%	22.97%	30.52%
DEP_Q Depr.	10.2	11.3	9.3
INT_Q Interest	5.6	6.5	5.1
PBT_Q Profit Before Tax	63	-3	59.4
TAX_Q Tax	16	12.7	14.9
NP_Q Net Profit	47	-15.7	44.5
EPS_adj_Q EPS Adj. latest	7.3	-2.4	6.9
NP_TTM Net profit TTM	-	-	-
EPS_TTM Basic EPS TTM	-	-	-
earnings_transcripts Earnings Transcripts
results_pdf Results PDF
result_notes Result Notes	Notes

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

VIEW ALL TABLE IN FINANCIAL PAGE

Symbiotec Pharmalab Technical Analysis

Symbiotec Pharmalab EMA & SMA

Bullish+3

4 bullish, 1 bearish

Bullish4

Bearish1

5 Day	1247
10 Day	1232.5
12 Day	1226.2

20 Day	1203.7
26 Day	1187.7

Symbiotec Pharmalab Delivery And Volume

Daily Avg. Delivery Volume %

30 Oct, 202636.2%

Week39.2%

Month33.7%

Symbiotec Pharmalab Active Candlesticks

Long Legged Doji Uptrend Rickshaw Man Uptrend

Legend

Positive IndicatorNeutral IndicatorNegative Indicator

Symbiotec Pharmalab Resistance and Support

1243.60

Pivot

First Resistance	1270.2
Second Resistance	1294.1
Third Resistance	1320.7

First Support	1219.7
Second Support	1193.1
Third Support	1169.2

Day RSI	57.6
Day MACD	37.7
Day MFI	80.2
Day MACD Signal Line	32.9

Symbiotec Pharmalab Beta

1 Month	0.9
1 Year	-

3 Month	-
3 Year	-

Symbiotec Pharmalab Price Change Analysis

↑5.9%

Over 1 Month

LowHigh

1067.61309.9

↑26.1%

Over 3 Months

LowHigh

934.21309.9

↑26.1%

Over 6 Months

LowHigh

934.21309.9

↑26.1%

Over 1 Year

LowHigh

934.21309.9

Symbiotec Pharmalab Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026

Name	Category	Shares	Shares %
Satwani Holdings Llp	Promoter	9,819,885	15.3 %
Rosewood Investments	Public	9,042,092	14.1 %
Business Excellence Trust Iii - India Business Excellence Fund Iii	Dii	6,578,995	10.2 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Symbiotec Pharmalab Deals - Insider, Bulk, Block and SAST

Client Name	Deal Type	Action	Date	Avg. Price	Quantity	Exchange
JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	Sell	02 Sep 2026	1123.68	357,516	NSE
JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	Purchase	02 Sep 2026	1123.40	357,516	NSE
GOLDMINE STOCKS PRIVATE LIMITED	Bulk	Sell	01 Sep 2026	1073.42	573,716	NSE
ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED	Bulk	Sell	01 Sep 2026	1074.04	547,601	NSE
YUGA STOCKS AND COMMODITIES PRIVATE LIMITED	Bulk	Sell	01 Sep 2026	1057.63	446,917	NSE
NK SECURITIES RESEARCH PRIVATE LIMITED	Bulk	Sell	01 Sep 2026	1063.88	842,160	NSE
PURE BROKING PRIVATE LIMITED	Bulk	Sell	01 Sep 2026	1049.44	627,323	NSE
GRT STRATEGIC VENTURES LLP	Bulk	Sell	01 Sep 2026	1069.40	403,571	NSE
IRAGE BROKING SERVICES LLP	Bulk	Sell	01 Sep 2026	1057.96	928,711	NSE
JUNOMONETA FINSOL PRIVATE LIMITED	Bulk	Sell	01 Sep 2026	1066.89	1,847,308	NSE

All deals

All insider trades

Symbiotec Pharmalab Corporate Actions

Symbiotec Pharmalab Board Meetings

Symbiotec Pharmalab past and upcoming board meetings.

#Ex-Date	Purpose	Notes
105 Nov 2026	Quarterly Results	-
221 Sep 2026	Quarterly Results	-

All Corporate Actions

Symbiotec Pharmalab Research Reports

Symbiotec Pharmalab research reports with share price targets, and buy/hold/sell recommendations from top brokers.

# Date	Broker Name	Target	Price When Recommended	Type	Upside	Change Since Recommendation	Links
125 Oct 2026	Motilal Oswal	1430	1164.2	Buy	22.83%	7.05%	pdf
230 Sep 2026	ICICI Direct	1540	1198	Buy	28.55%	4.03%	pdf
323 Aug 2026	Deven Choksey	-	-	IPO Subscribe	-	-%	pdf
420 Aug 2026	ICICI Direct	-	-	IPO Subscribe	-	-%	pdf
519 Aug 2026	Ventura	-	-	IPO Subscribe	-	-%	pdf

All Reports of Symbiotec

Symbiotec Pharmalab Corporate Filings

Symbiotec Pharmalab BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

Date	Announcement Title	Details	Links
28 Oct 2026	Symbiotec Pharmalab Ltd - 544889 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	Earnings Conference Call / Analysts Meet to discuss the financial performance and business updates for the quarter and half year ended September 30, 2026 (Q2FY27). The Earnings Conference Call is scheduled to be held on Friday, November 06, 2026 at 09:30 A.M. IST, through virtual/audio conference call. The call is being hosted by Avendus Spark. The schedule of the aforesaid call is subject to change due to exigencies, if any. Kindly note that no unpublished price sensitive information shall be shared during the call. The above information is also being made available on the website of the Company at investor.symbiotec.com	PDF
28 Oct 2026	Symbiotec Pharmalab Ltd - 544889 - Board Meeting Intimation for Prior Intimation Of The Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Thursday, November 05, 2026	Symbiotec Pharmalab Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve To consider and approve the Unaudited Standalone and Consolidated Financials Results for the quarter and half year ended September 30, 2026 along with Limited Review Report.	PDF
16 Oct 2026	Symbiotec Pharmalab Ltd - 544889 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.	The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 16, 2026 for Anil Satwani, Sushil Satwani, Kashish Satwani, Satwani Holdings LLP, Kashish and Anil Satwani Family Trust, Arjun Anil Satwani Family Trust & Krishna Anil Satwani Family Trust	PDF
05 Oct 2026	Symbiotec Pharmalab Ltd - 544889 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	Certificate Pursuant to regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026.	PDF
30 Sep 2026	Symbiotec Pharmalab Ltd - 544889 - Symbiotec''s Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agreement With A Leading Global Pharmaceutical Company For Dual Chamber Vial Products In The U.S.	Symbiotec''s Wholly Owned Subsidiary Knovea Pharmaceutical enters into strategic commercialization agreement with a leading global pharmaceutical company for Dual Chamber Vial (''DCV'') products in the U.S.	PDF

VIEW ALL

Symbiotec Pharmalab DocumentsAsk MarketMind AI

Symbiotec Pharmalab Earnings Call

Symbiotec Pharmalab earnings calls, including management commentary and AI-generated summaries.

Date	Title	Links
28 Sep 2026	Symbiotec Pharmalab Ltd - 544889 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript	Link
22 Sep 2026	Symbiotec Pharmalab Ltd - 544889 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome	Link
22 Sep 2026	Symbiotec Pharmalab Results Earnings Call for Q1FY27	Audio Video

view all

Symbiotec Pharmalab Investor Presentations

Symbiotec Pharmalab investor presentations, including business updates, financial insights, and strategic initiatives.

Date	Report Title	Links
21 Sep 2026	Symbiotec Pharmalab Ltd - 544889 - Announcement under Regulation 30 (LODR)-Investor Presentation	Link

Symbiotec Pharmalab - Company Profile

Symbiotec Pharmalab Management Structure

Symbiotec Pharmalab management structure with salaries, total experience, and qualifications.

NAME	DESIGNATION	GROSS REMUNERATION ₹(LAC)	AS OF
Mr. Sushil Satwani	Director(Commercial),Promoter	225	Mar 26
Mr. Anant Achyut Deshpande	President(Operations)	166	Mar 26
Mr. Raghavender Ramachandran	Chief Financial Officer	136.1	Mar 26
Mr. Parakalan Srinivasan	Senior Vice President.(Operations,Projects.)	123.6	Mar 26
Mr. Dharm Shanker Pandey	Vice President(Quality Assurance)	112.8	Mar 26
Mr. Raman Prasad	Vice President(Research & Development,Manufacturing)	104.8	Mar 26
Mr. Nishikant Digambar Ghadge	Vice President(Research & Development,Manufacturing)	95.2	Mar 26
Mr. Shubham Saboo	General Manager	89.4	Mar 26
Mr. Suman Podder	Associate Vice President(Regulatory Affairs)	82.6	Mar 26
Mr. Sandeep Patil	Chief Technology Officer	69.6	Mar 26
Mr. Saurabh Sahu	Associate Vice President(Research & Development)	65.9	Mar 26
Mr. Vijay Bajpai	Chief Human Resources Officer(Human Resources)	61.3	Mar 26
Mr. Kapil Mishra	Head(Strategy)	59.3	Mar 26
Ms. Kashish Satwani	President(Human Resources),Promoter	35.3	Mar 26
Salil Jain	Company Secretary,Compliance Officer	14.9	Mar 26

Symbiotec Pharmalab Board of Directors

Symbiotec Pharmalab Board of directors with salaries, total experience, and qualifications.

NAME	POSITION	GROSS REMUNERATION ₹(LAC)	AS OF
ANIL KUMAR SATWANI	Chairman / Executive Director / M D / Promoter	809.1	Mar 26
Salil Jain	Company Sec. & Compli. Officer	14.9	Mar 26
Sunita Kishnani	Independent Non Exe. Director	2	Mar 26
PRATIK PATEL	Independent Non Exe. Director	1.5	Mar 26
ROHIT BRIJMOHAN MANTRI	Nominee	-	Mar 26
Pramod Kasat	Independent Non Exe. Director	-	Mar 26
Dhananjay N Mungale	Nominee	-	Mar 26

Website: www.symbiotec.com

About the company - Business Profile

Symbiotec Pharmalab was incorporated on September 20, 2002. The company is an R&D-driven;, science-based pharmaceutical and biotechnology player with capabilities in organic chemistry, biotechnology, and complex injectables, and a global leadership position in corticosteroid and steroidal-hormone APIs. It is the only Indian and global company present across the top 10 such APIs in FY25, manufacturing them through fermentation and complex multi-step chemical processes

Symbiotec Pharmalab FAQ

Symbiotec Pharmalab today is trading in the red, down by 0.31% at ₹1,246.3.

Symbiotec Pharmalab is currently trading down 0.31% on an intraday basis. In the past week the stock rose 7.05%. Stock has been up 26.14% in the past quarter and rose 26.14% in the past year. You can view this in the share price history/seasonality section.

Symbiotec Pharmalab is listed on NSE with the ticker SYMBIOTEC and on BSE as 544889. It's currently trading on NSE at a share price of ₹1,246.3 and on BSE with a share price of ₹1,243.5.

The market cap of Symbiotec Pharmalab is ₹8,008.24 Cr. as of Oct 30, 2026.

Symbiotec Pharmalab has never announced any dividend since the time of its listing on the BSE/NSE exchanges.

Symbiotec Pharmalab has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.

Symbiotec Pharmalab reported ₹218.49 Cr. in revenue, ₹14.06 Cr. in net profit, and ₹45.54 Cr. in EBITD as of Sep 21, 2026 for Q1 FY26-27.

There are no analyst predictions for stock price target for Symbiotec Pharmalab.

The PE ratio of Symbiotec Pharmalab is not available as of Nov 01, 2026.

The PB ratio of Symbiotec Pharmalab is 6.96 as of Oct 30, 2026.

You can view the latest analyst reports on the Symbiotec Pharmalab reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.

Key Metrics
DVM
Price Chart
Forecaster
Financials
Technicals
Shareholding
Deals
Documents
Corporate actions
Company Profile

Symbiotec Pharmalab Live Share Price Today, Share Analysis and Chart

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Symbiotec Pharmalab Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Symbiotec Pharmalab - Quarterly

Symbiotec Pharmalab quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue Symbiotec Pharmalab Jun-2026 Quarterly Revenue is Rs 230 Cr which is growth of 6.8% YoY.

Quarterly Net Profit Symbiotec Pharmalab Jun-2026 Quarterly Net Profit is Rs 47 Cr which is growth of 5.6% YoY.

Symbiotec Pharmalab Technical Analysis

Symbiotec Pharmalab EMA & SMA

Symbiotec Pharmalab Delivery And Volume

Symbiotec Pharmalab Active Candlesticks

Symbiotec Pharmalab Resistance and Support

Symbiotec Pharmalab Beta

Symbiotec Pharmalab Price Change Analysis

Symbiotec Pharmalab Shareholding Pattern/ Ownership

Shareholding Summary

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

Symbiotec Pharmalab Deals - Insider, Bulk, Block and SAST

Bulk Block Deals

Insider Trading & SAST

Symbiotec Pharmalab Corporate Actions

Symbiotec Pharmalab Board Meetings

Symbiotec Pharmalab past and upcoming board meetings.

Symbiotec Pharmalab Research Reports

Symbiotec Pharmalab research reports with share price targets, and buy/hold/sell recommendations from top brokers.

Symbiotec Pharmalab Corporate Filings

Symbiotec Pharmalab BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

Symbiotec Pharmalab DocumentsAsk MarketMind AI

Symbiotec Pharmalab Earnings Call

Symbiotec Pharmalab earnings calls, including management commentary and AI-generated summaries.

Symbiotec Pharmalab Investor Presentations

Symbiotec Pharmalab investor presentations, including business updates, financial insights, and strategic initiatives.

Symbiotec Pharmalab - Company Profile

Symbiotec Pharmalab Management Structure

Symbiotec Pharmalab management structure with salaries, total experience, and qualifications.

Symbiotec Pharmalab Board of Directors

Symbiotec Pharmalab Board of directors with salaries, total experience, and qualifications.

About the company - Business Profile

Symbiotec Pharmalab FAQ

How is Symbiotec Pharmalab today?

Symbiotec Pharmalab today is trading in the red, down by 0.31% at ₹1,246.3.

How has Symbiotec Pharmalab performed historically?

Symbiotec Pharmalab is currently trading down 0.31% on an intraday basis. In the past week the stock rose 7.05%. Stock has been up 26.14% in the past quarter and rose 26.14% in the past year. You can view this in the share price history/seasonality section.

What is the current share price of Symbiotec Pharmalab on NSE and BSE exchanges?

Symbiotec Pharmalab is listed on NSE with the ticker SYMBIOTEC and on BSE as 544889. It's currently trading on NSE at a share price of ₹1,246.3 and on BSE with a share price of ₹1,243.5.

What is the market cap of Symbiotec Pharmalab?

The market cap of Symbiotec Pharmalab is ₹8,008.24 Cr. as of Oct 30, 2026.

When did Symbiotec Pharmalab last pay a dividend, and what has its dividend history been?

Symbiotec Pharmalab has never announced any dividend since the time of its listing on the BSE/NSE exchanges.

Has Symbiotec Pharmalab issued any bonus shares or share splits recently?

Symbiotec Pharmalab has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.

What do the financial statements and annual reports of Symbiotec Pharmalab Indicate?

Symbiotec Pharmalab reported ₹218.49 Cr. in revenue, ₹14.06 Cr. in net profit, and ₹45.54 Cr. in EBITD as of Sep 21, 2026 for Q1 FY26-27.

What is the target share price of Symbiotec Pharmalab according to analyst predictions in FY26-27?

There are no analyst predictions for stock price target for Symbiotec Pharmalab.

What is the PE Ratio of Symbiotec Pharmalab?

The PE ratio of Symbiotec Pharmalab is not available as of Nov 01, 2026.

What is the PB Ratio of Symbiotec Pharmalab?

The PB ratio of Symbiotec Pharmalab is 6.96 as of Oct 30, 2026.

Where can I check the latest Research Reports about Symbiotec Pharmalab?

You can view the latest analyst reports on the Symbiotec Pharmalab reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.

How can I be notified of real time alerts about Symbiotec Pharmalab stock?

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.